AbbVie recently showcased significant advances in oncology, particularly with the introduction of new pipeline products like ABBV-969 and ABBV-514 at the AACR Annual Meeting 2025, reflecting a ...

It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

AbbVie’s stock is doing a financial cha-cha—up slightly today but analysts predict it’ll drop by 11.59%. Despite technical indicators waving buy flags across the board, analysts think the party may ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 20 unusual trades. Delving into the details, we found 45% of traders were ...

AbbVie has had a dramatic year, juggling a Humira hangover, political landmines, and a costly failed drug trial. Despite a major flop on a $9 billion acquisition, AbbVie’s new immunology duo, Skyrizi ...

There is change at the top of AbbVie’s R&D organisation, as chief scientific officer Thomas Hudson announces his retirement after four years in the role. He will be replaced as head of AbbVie ...